home / stock / mtcr / mtcr news

MTCR News and Press, Metacrine Inc. From 03/09/21

Stock Information
Company Name: Metacrine Inc.
Stock Symbol: MTCR
Market: OTC
Website: metacrine.com
Menu
MTCR MTCR Quote MTCR Short MTCR News MTCR Articles MTCR Message Board
Get MTCR Alerts

News, Short Squeeze, Breakout and More Instantly...
MTCR - Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been trea...
MTCR - Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, pre...

MTCR - Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, pres...

MTCR - Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the Journal of Hepatology ha...
MTCR - Metacrine's MET642 Fast Track'd in U.S. for NASH, shares up 11%

The FDA has granted Fast Track designation to Metacrine's(MTCR) MET642, the second farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis ((NASH)).Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing ...

MTCR - Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Adminis...

MTCR - Metacrine initiates mid-stage MET409 + empagliflozin study in diabetes and NASH

The first patient has been treated in Metacrine's (MTCR) Phase 2a trial evaluating MET409 (50 mg) in combination with empagliflozin (Jardiance), in patients with both type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis ((NASH)). The 12-week trial will enroll up to 120 patients in...
MTCR - Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been treat...

MTCR - Metacrine Reports Positive Results from Phase 1 Trial of MET642

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21 SAN DIEGO, Dec. 17, 2020 (...

MTCR - SCWorx, Oramed Pharmaceuticals leads healthcare gainers; AnPac Bio-Medical Science, Sientra among major losers

Gainers: SCWorx (WORX) +90%, Oramed Pharmaceuticals (ORMP) +31%, Rhythm Pharmaceuticals (RYTM) +19%, Genfit (GNFT) +15%, Verastem (VSTM) +13%.Losers: AnPac Bio-Medical Science (ANPC) -11%, Sientra (SIEN) -9%, Alphatec Holdings (ATEC)...
Previous 10 Next 10